Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe’s Coverage of ESCMID Global Congress 2026

Meiji Seika Pharma says Lancet Microbe and ESCMID 2026 coverage highlights global Phase III Integral-2 results for its novel β-lactamase inhibitor nacubactam. The article provides no specific efficacy/safety figures or regulatory/capital implications, so expected price impact appears limited.